{"id":3444,"date":"2019-05-31T15:58:15","date_gmt":"2019-05-31T15:58:15","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=3444"},"modified":"2024-11-08T08:17:57","modified_gmt":"2024-11-08T08:17:57","slug":"france-anses-epoxiconazole-based-products-ban","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/","title":{"rendered":"FRANCE &#8211; ANSES: Epoxiconazole-based products ban"},"content":{"rendered":"<p><strong>On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing authorisations of epoxiconazole-based products was announced.<\/strong><\/p>\n<p>Epoxiconazole is a fungicide active substance listed as candidate for substitution by <a href=\"https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/PDF\/?uri=CELEX:32015R0408&amp;from=EN\" target=\"_blank\" rel=\"noopener noreferrer\">Regulation (EU) \u00a02015\/408<\/a>. This substance is persistent and toxic, a suspected carcinogen (C2) and presumed human reproductive toxicant (R1B). The authorisation of epoxiconazole is under evaluation at EU level. A decision should be taken by 30 April 2020.<\/p>\n<p>Further to the adoption of the European legislation on endocrine disruptors in December 2017 and to the implementation of the guidance document on identification published on 5 June 2018, ANSES immediately issued an internal assessment of endocrine-disrupting properties of epoxiconazole.<\/p>\n<p>Based on this evaluation, Anses have concluded that epoxiconazole is an endocrine disruptor for humans and non-target organisms.<\/p>\n<p>For this reason, ANSES has notified the authorisation holders of its intention to withdraw 76 epoxiconazole-based products from the French \u00a0market.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>To download:<\/strong><\/p>\n<p><a href=\"https:\/\/www.anses.fr\/en\/system\/files\/PHYTO2018SA0289.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">ANSES OPINION on endocrine-disrupting properties of epoxiconazole (in French)<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Lynxee consulting<\/strong>\u2019s team is at your disposal to answer your questions.<\/p>\n<p><strong>Contact us!<\/strong> <a href=\"https:\/\/lynxee.consulting\/en\/contact\/\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/lynxee.consulting\/en\/contact\/<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h6>Cr\u00e9dit photo : NoName_13\/pixabay<\/h6>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing authorisations of epoxiconazole-based products was<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":5,"featured_media":3429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[118,181],"class_list":["post-3444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-endocrine-disruptors","tag-perturbateurs-endocriniens-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>FRANCE - ANSES: Epoxiconazole-based products ban - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FRANCE - ANSES: Epoxiconazole-based products ban - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-31T15:58:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-08T08:17:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"490\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karine Mavet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karine Mavet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/\",\"url\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/\",\"name\":\"FRANCE - ANSES: Epoxiconazole-based products ban - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\/\/lynxee.consulting\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg\",\"datePublished\":\"2019-05-31T15:58:15+00:00\",\"dateModified\":\"2024-11-08T08:17:57+00:00\",\"author\":{\"@id\":\"https:\/\/lynxee.consulting\/#\/schema\/person\/a2a6161ec6591c6ae990f836d8ae4f63\"},\"description\":\"On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing\",\"breadcrumb\":{\"@id\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#primaryimage\",\"url\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg\",\"contentUrl\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg\",\"width\":1920,\"height\":490},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/lynxee.consulting\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FRANCE &#8211; ANSES: Epoxiconazole-based products ban\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lynxee.consulting\/#website\",\"url\":\"https:\/\/lynxee.consulting\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lynxee.consulting\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/lynxee.consulting\/#\/schema\/person\/a2a6161ec6591c6ae990f836d8ae4f63\",\"name\":\"Karine Mavet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lynxee.consulting\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2015\/05\/karine-96x96.jpg\",\"contentUrl\":\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2015\/05\/karine-96x96.jpg\",\"caption\":\"Karine Mavet\"},\"sameAs\":[\"https:\/\/lynxee.consulting\"],\"url\":\"https:\/\/lynxee.consulting\/en\/author\/karine\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FRANCE - ANSES: Epoxiconazole-based products ban - Lynxee consulting","description":"On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/","og_locale":"en_US","og_type":"article","og_title":"FRANCE - ANSES: Epoxiconazole-based products ban - Lynxee consulting","og_description":"On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing","og_url":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/","og_site_name":"Lynxee consulting","article_published_time":"2019-05-31T15:58:15+00:00","article_modified_time":"2024-11-08T08:17:57+00:00","og_image":[{"width":1920,"height":490,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg","type":"image\/jpeg"}],"author":"Karine Mavet","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Karine Mavet","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/","url":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/","name":"FRANCE - ANSES: Epoxiconazole-based products ban - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg","datePublished":"2019-05-31T15:58:15+00:00","dateModified":"2024-11-08T08:17:57+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/a2a6161ec6591c6ae990f836d8ae4f63"},"description":"On 28 May 2019, Anses opinion on endocrine-disrupting properties of the active substance epoxiconazole was published and the \u00a0withdrawal of marketing","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2019\/06\/field-1478763_1920.jpg","width":1920,"height":490},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/france-anses-epoxiconazole-based-products-ban\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"FRANCE &#8211; ANSES: Epoxiconazole-based products ban"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/a2a6161ec6591c6ae990f836d8ae4f63","name":"Karine Mavet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/image\/","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2015\/05\/karine-96x96.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2015\/05\/karine-96x96.jpg","caption":"Karine Mavet"},"sameAs":["https:\/\/lynxee.consulting"],"url":"https:\/\/lynxee.consulting\/en\/author\/karine\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/3444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=3444"}],"version-history":[{"count":3,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/3444\/revisions"}],"predecessor-version":[{"id":7542,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/3444\/revisions\/7542"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/3429"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=3444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=3444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=3444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}